NCT04883593View on ClinicalTrials.gov

A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

September 3, 2020

Primary Completion Date

February 20, 2021

Study Completion Date

February 20, 2021

Conditions
Tinea Pedis
Interventions
DRUG

TA103

The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.

DRUG

Placebo Control

The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.

Trial Locations (1)

28217

Catawba Research, LLC, Charlotte

All Listed Sponsors
lead

Sun Pharmaceutical Industries, Inc.

INDUSTRY

NCT04883593 - A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis. | Biotech Hunter | Biotech Hunter